47.05CHF+1.18%Mkt Cap: 1.77B $P/E: —1d ago
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceut…
Industry Peers
Drug Manufacturers - Specialty & Genericvs Drug Manufacturers - Specialty & Generic
P/B
Pricier
1M Perf
Lower
Indicators:|
Key Statistics
Company
Market Cap1.77B $
Enterprise Value1.85B $
Revenue (TTM)444.34M $
Gross Profit75.94M $
Net Income (TTM)-24.16M $
Revenue/Share13.47 USD
Last Price47.05 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees1.4K
CountryCH
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)36.01
PEG—
EV/EBITDA42.52
EV/Revenue4.16
P/S3.99
P/B4.95
EPS (TTM)-0.59
EPS (Forward)1.31
52W Range
19.86100% of range47.10
52W High47.10 CHF
52W Low19.86 CHF
Profitability
Gross Margin16.98%
Oper. Margin9.99%
EBITDA Margin9.78%
Profit Margin-5.40%
ROE-6.22%
ROA-2.56%
Growth
Revenue Growth10.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF88.46M $
CapEx (TTM)124.29M $
FCF Margin-11.25%
FCF Yield-2.82%
Net Debt76.21M $
Net Debt/EBITDA1.75
Balance Sheet
Debt/Equity0.38
Current Ratio1.74
Quick Ratio0.87
Book Value/Sh9.506 CHF
Cash/Share2.260 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 28, 2022
Pay DateMay 2, 2022
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)38.50 CHF
Upside (mean)-18.2%
Target Range25.56 CHF – 45.01 CHF
CHF25.56-18.2% to meanCHF45.01
# Analysts6
Ownership
Shares Out.33.01M
Float12.96M
Insiders60.52%
Institutions20.37%
Technical
SMA 5037.78 (+24.5%)
SMA 20029.00 (+62.3%)
Beta1.03
S&P 52W Chg20.05%
Avg Vol (30d)55.75K
Avg Vol (10d)79.03K
Technical Indicators
RSI (14)78.8
MACD2.1735
MACD Signal0.9666
MACD Hist.+1.2069
BB Upper46.31 CHF
BB Middle38.21 CHF
BB Lower30.10 CHF
BB Width42.43%
ATR (14)1.878 CHF
Vol Ratio (20d)0.61x